Using sitagliptin to treat newly diagnosed type 2 diabetes
Effectiveness of Sitagliptin for the Treatment of Newly Diagnosed Type 2 Diabetes
This study is testing if the diabetes medication sitagliptin can help people who have just been diagnosed with type 2 diabetes manage their blood sugar and improve their gut health.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Beijing Chao Yang Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT04495881 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients who have recently been diagnosed with type 2 diabetes. Over a period of three months, 50 participants will receive sitagliptin treatment while their gut microbiome and various health indicators, such as blood glucose levels and cholesterol, will be monitored. The study aims to understand how sitagliptin affects diabetes management and the gut microbiome. Data will be collected through patient assessments and fecal samples before and after treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 who have been newly diagnosed with type 2 diabetes and have an HbA1c level of 7% or higher.
Not a fit: Patients with a history of certain medical conditions, such as pancreatitis, coronary artery disease, or those currently on anti-diabetic medications, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how sitagliptin treatment can improve diabetes management and gut health in newly diagnosed patients.
How similar studies have performed: Previous studies have shown the effectiveness of sitagliptin in managing type 2 diabetes, making this approach well-supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18-65 years old newly diagnosed with type 2 diabetes * HbA1c ≥ 7% Exclusion Criteria: * The positive of diabetes antibodies * Anti-diabetic drugs therapy before participation * Pancreatitis * Coronary artery disease * Liver function impairment * Renal function impairment * History of intestinal surgery * Chronic hypoxic diseases (emphysema and cor pulmonale) * Infectious disease * Hematological disease * Systemic inflammatory disease * Cancer * Pregnant * Ingesting agents known to influence glucose or lipid metabolism; * Any antibiotics or probiotics in the past three months prior to the study.
Where this trial is running
Beijing, Beijing
- Beijing Chao-Yang Hospital, Capital Medical University — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Guang Wang, MD — Beijing Chao Yang Hospital
- Study coordinator: Jia Liu, MD
- Email: liujia0116@126.com
- Phone: 010-85231710
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.